Table 1 Characteristics of 239 patients investigated for Neoehrlichia mikurensis
From: Neoehrlichia mikurensis in Danish immunocompromised patients: a retrospective cohort study
Number of patients | |
|---|---|
Age, median (IQR) | 65 (51–73) |
Male: Female | 139:100 |
Received immunosuppressive therapy within one year prior to blood sampling, n(%) | 91 (38) |
Treatment | |
Monoclonal anti-CD20 antibodies, n(%) | 197 (82.4) |
TNF-α inhibitors1, n(%) | 27 (11.3) |
Other2, n(%) | 15 (6.3) |
Diagnoses | |
Lymphoma3, n(%) | 106 (44.3) |
Chronic lymphocytic leukemia, n(%) | 57 (23.7) |
Acute lymphocytic leukemia, n(%) | 10 (4.2) |
Chronic myeloid leukemia, n(%) | 8 (3.3) |
Acute myeloid leukemia, n(%) | 8 (3.3) |
Idiopathic thrombocytopenic purpura, n(%) | 7 (2.9) |
Myelodysplastic syndrome, n(%) | 6 (2.5) |
Autoimmune hemolytic anemia, n(%) | 4 (1.7) |
Arthritis4, n(%) | 9 (3.7) |
Waldenström macroglobulinemia | 8 (3.3) |
Wegener’s granulomatosis, n(%) | 6 (2.5) |
Systemic lupus erythematosus, n(%) | 4 (1.7) |
Other5, n(%) | 7 (2.9) |